TY - JOUR
AU - Young, M. A.
AB - 
Objective: Troglitazone is an agonist of the peroxisome proliferator-activated receptor-γ (PPAR-γ), which has been shown to improve the metabolic control of type 2 diabetes. Troglitazone undergoes hepatic metabolism to an inactive sulphate conjugate and an oxidative quinone metabolite with minor activity. The objective of this study was to compare the pharmacokinetics of troglitazone in patients with hepatic insufficiency and normal subjects.
TI - Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency
JF - European Journal of Clinical Pharmacology
DO - 10.1007/s002280050514
DA - 1998-10-14
UR - https://www.deepdyve.com/lp/springer-journals/pharmacokinetics-of-troglitazone-a-ppar-agonist-in-patients-with-JCietI37IH
SP - 567
EP - 571
VL - 54
IS - 7
DP - DeepDyve
ER -